Drug intelligence / Profile preview

CIGB-258

Development stage: Unknown
Lead developer: Center for Genetic Engineering and Biotechnology
Modality: Peptides
Administration: Intravenous

Overview

CIGB-258 is an immunoregulatory peptide derived from the human heat shock protein 60 (HSP60). It exhibits anti-inflammatory properties and has been studied for its potential in treating conditions associated with hyperinflammation, such as COVID-19 and rheumatoid arthritis. The peptide increases regulatory T cell activity and reduces inflammation by modulating cytokine levels.

Brand names: Jusvinza
Other names: CIGB-258 peptideCIGB258 peptideCIGB 258 peptide

Targets

IL-17A (Interleukin-17A)TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)IFNG (Interferon gamma)

Beyond the preview

Go deeper on CIGB-258.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIGB-258.

Explore the full profile